Document is current
Any future updates will be listed below
-
Authors
Ständer, Sonja https://orcid.org/0000-0003-3612-7786
Yosipovitch, Gil https://orcid.org/0000-0001-6303-1822
Simpson, Eric L. https://orcid.org/0000-0003-0853-0252
Kim, Brian S. https://orcid.org/0000-0002-8100-7161
Kabashima, Kenji https://orcid.org/0000-0002-0773-0554
Thaçi, Diamant https://orcid.org/0000-0001-8513-550X
Metz, Martin https://orcid.org/0000-0002-4070-9976
Chen, Zhen
Hagen, Sandra
Bastian, Mike https://orcid.org/0000-0001-8347-7426
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02395133 at ClinicalTrials.govDocuments that mention this clinical trial
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials
https://doi.org/10.1007/s12325-025-03124-8
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi
- License Information
-
More Information
Article History
Received: 14 November 2024
Accepted: 21 January 2025
First Online: 19 February 2025
Declarations
:
: Sonja Ständer is an investigator for Celldex, Galderma, GSK, Incyte, Kiniksa Pharmaceuticals, and Trevi Therapeutics; a consultancy/advisory board member for AbbVie, Almirall, Beiersdorf, Clexio Biosciences, Eli Lilly, Galderma, Incyte, Integrity CE, Kiniksa Pharmaceuticals, KliRNA Biotech, Pfizer, Professor Paul Gerson Unna Academy, Sanofi, Touch IME, Vifor Pharma, and WebMD; and a speaker for AbbVie, BMS, Eli Lilly, FOMF, Galderma, LEO Pharma, L'Oréal, MEDahead, moroscience, Novartis, Pfizer, Professor Paul Gerson Unna Academy, Sanofi, UCB, and Vifor Pharma. Gil Yosipovitch is an advisory board member for AbbVie, Almirall, Amgen, Arcutis, Celldex, Eli Lilly, Escient Health, Galderma, GSK, Kamari, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, and Vifor Pharma; received grants/research funding from AbbVie, Celldex, Galderma, Eli Lilly, Escient, LEO Pharma, Novartis, Pfizer, and Sanofi-Regeneron Pharmaceuticals Inc.; and is an investigator for Sanofi-Regeneron Pharmaceuticals Inc. Eric L. Simpson has received personal fees from AbbVie, Amgen, Arcutis Biotherapeutics, Areteia Therapeutics, BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Biosciences, Galderma, Gilead, GlaxoSmithKline, Impetus Healthcare, Incyte, Innovaderm Research, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Merck, Numab Therapeutics, Pfizer, Physicians World, PRImE, Recludix Pharma, Regeneron Pharmaceuticals Inc., Roivant Sciences, Sanofi/Genzyme, Sitryx Therapeutics, Trevi Therapeutics, and Valeant; and reports grants (or serves as Principal investigator) for AbbVie, Acrotech, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Castle Biosciences, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, LEO Pharma, National Jewish Health, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target, and VeriSkin. Brian S. Kim is co-founder of Alys Pharmaceuticals; has served as a consultant for 23andMe, ABRAX Japan, AbbVie, Amgen, Attovia Therapeutics, Cara Therapeutics, Clexio Biosciences, Eli Lilly and Company, Escient Pharmaceuticals, Evommune, Galderma, LEO Pharma, Micreos, Novartis, Pfizer, Recens Medical, Regeneron, Sanofi, Septerna, Teva, Trevi Therapeutics, Triveni Bio, WebMD; has stock in ABRAX Japan, Alys Pharmaceuticals, Attovia Therapeutics, Locus Biosciences, Recens Medical, and Triveni Bio; holds a patent for the use of JAK1 inhibitors for chronic pruritus. Kenji Kabashima has received honoraria for lectures from Eli Lilly, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, and Procter & Gamble; and research grants from Kyoto Hakko Kirin, Mitsubishi Tanabe Pharma, and Ono Pharmaceutical. Diamant Thaçi is an advisor, speaker, or consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Janssen, Kyowa Kirin, LEO Pharma, Lilly, L'Oréal, New Bridge, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi/Genzyme, Target RWE, UCB, and Vichy. Martin Metz has received honoraria as a speaker and/or advisor for AbbVie, ALK-Abello, Almirall, Amgen, argenx, AstraZeneca, Bayer, Beiersdorf, Celldex, Celltrion, Escient Pharmaceuticals, Galderma, GSK, Incyte, Jasper, Novartis, Pfizer, Pharvaris, Regeneron Pharmaceuticals Inc., Sanofi, Teva, Third Harmonic Bio, and Vifor Pharma. Zhen Chen and Sandra Hagen are employees and shareholders of Regeneron Pharmaceuticals Inc. Mike Bastian is an employee and may hold stock and/or stock options in Sanofi.
: The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. An independent data and safety monitoring committee conducted blinded monitoring of patient safety data. The local institutional review board or ethics committee at each study center oversaw trial conduct and documentation. Signed written informed consent was obtained from all patients participating in both trials.
